What happens when you stop Mounjaro? The honest answer

The trial extension data

The clearest published evidence comes from two trial extensions. STEP-1 extension (Wilding et al., 2022) followed patients from the original semaglutide / Wegovy trial. The 2.4mg group, who had lost 17.3% of body weight by week 68 of active treatment, were then switched off the drug. By week 120 (one year off treatment), they had regained approximately two-thirds of the lost weight — leaving them with about 5% sustained loss versus baseline. Cardiometabolic improvements similarly reversed.

SURMOUNT-4 (Aronne et al., 2024) tested the same question for tirzepatide. Patients reached a mean 20.9% loss by week 36. Half were then randomised to continue tirzepatide, half to placebo. By week 88 (52 weeks of placebo): the continuation group had lost a further 5.5%; the placebo group regained 14% of body weight, ending with 9.9% net loss versus baseline. So roughly two-thirds of the lost weight came back within a year of stopping.

Both numbers are averages. Individual experience varies. About 20% of patients in these extension studies maintained most of their loss; about 20% regained essentially all of it; the rest fell somewhere in between.

The biology: set-point, leptin and ghrelin

The body defends its body weight. This is not a moral failing — it's homeostasis. After significant weight loss, leptin levels drop (signalling 'low fat stores' to the brain), ghrelin rises (signalling 'hungry'), and the basal metabolic rate adjusts downward by more than expected from the loss of body mass alone. This package of changes is what researchers call the 'metabolic adaptation to weight loss' and it persists for months to years after the loss. It's not unique to GLP-1 drugs — it happens after any meaningful weight loss, dieting, bariatric surgery, anything.

What GLP-1 drugs do is provide a pharmacological countermeasure to that adaptation. They suppress appetite and slow gastric emptying so that the lower set-point feels less like deprivation. Take the drug away, and the underlying drive returns. Hunger comes back. Cravings come back. Portion sizes feel small again. None of this is in your head — it's measurable hormonally and behaviourally.

Gradual taper vs cold-stop

The SmPCs for both Mounjaro and Wegovy don't mandate a taper. Pharmacokinetically, the drugs wash out in about five to six weeks regardless of how you stop. So 'taper' here doesn't mean letting the drug levels fall slowly — it means letting your body and behaviours adjust gradually.

Our usual clinical approach for patients who want to come off:

1. Decide on the maintenance dose first. Often the lowest effective dose (Mounjaro 5–7.5mg, Wegovy 1mg) is sustainable indefinitely without needing the higher doses that caused initial loss.
2. If stopping entirely is the goal, step down through the doses over 8–12 weeks rather than cold-stop. This gives behavioural patterns time to consolidate.
3. Weigh weekly for the first three months after the last dose. Catching a 2–3kg rebound early is much easier to act on than catching a 10kg rebound at six months.
4. Plan the appetite return. Most patients describe a noticeable hunger increase by week 4–6 after the last dose. Have a protein-heavy meal-prep system already in place.

Lifestyle anchors that improve maintenance odds

Looking at who maintains their loss in the trial extensions and in our own clinic data, four things matter more than anything else:

• Strength training. Two to three sessions per week, full body. Resistance training preserves lean muscle mass (which protects basal metabolic rate) and improves insulin sensitivity. Patients who lift weights through and after their GLP-1 treatment maintain weight significantly better. This is the single most evidenced intervention.
• Protein intake. 1.2–1.6g per kg of target body weight per day. Protein is satiating, requires more energy to digest, and supports muscle. We work backwards from your goal weight, not your current weight, when calculating.
• Food environment design. What's in your fridge, what's in your cupboards, where you eat, what you eat in front of. The willpower model of eating doesn't survive contact with reality — your environment does the heavy lifting.
• Sleep. Less than 6 hours regularly is associated with elevated ghrelin, blunted leptin, and significantly increased weight regain.

Notably absent from this list: cardio. Aerobic exercise is wonderful for cardiovascular health but its direct effect on weight maintenance is small. Don't neglect it, but don't lean on it as the primary anchor.

When stopping is actually the right call

There are three legitimate reasons to stop:

1. Side effects. Persistent nausea that doesn't settle, gallbladder problems, pancreatitis, or any signal serious enough to alter the risk-benefit balance. See our GLP-1 side effects guide for what's normal and what's not.
2. Financial. If you can't sustain the cost long-term, planning a structured stop is better than running out of medication unexpectedly.
3. Pregnancy planning. Both Mounjaro and Wegovy must be stopped at least two months before a planned pregnancy. We support women planning conception with a structured pre-pregnancy plan.

Goal achievement alone (reaching your target weight) is not a strong reason to stop. The trial data shows that continuing at a maintenance dose preserves loss; stopping risks regain. Many patients now plan for indefinite low-dose maintenance, in the same way someone with hypertension stays on their blood pressure medication long-term.

Monitoring in the first three to six months post-stop

We recommend a structured monitoring plan:

• Weekly weigh-ins for three months, monthly thereafter
• Repeat HbA1c at three and six months (especially if you had prediabetes or T2D at baseline)
• Repeat lipid profile at six months
• Quarterly check-ins with us — we run a brief 15-minute review

If you regain more than 5% of body weight within the first six months, that's the early-warning signal for restarting. Restarting GLP-1 after a break is usually straightforward — we re-titrate from 2.5mg over several weeks. See our baseline blood panel guide for the monitoring panel content.

How to book a stop-planning consultation

If you're thinking about coming off Mounjaro or Wegovy, book a planning appointment with us before you do. We'll work through your taper schedule, behaviour anchors, monitoring plan, and what to do if regain starts. Book at traffordclinic.co.uk/weight-loss or call 0161 258 6149.

We see weight-management patients across Greater Manchester — Manchester, Altrincham, Sale, Chorlton, Salford Quays, and our home clinic in Old Trafford.

Related reading: Mounjaro vs Wegovy, GLP-1 side effects, Pre-Mounjaro baseline panel.